Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer

OBJECTIVE: Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime model for advancing development of tailored therapies. The p16-cyclin D-cyclin-dependent kinase 4/6-retinoblastoma (RB) protein (CDK4) pathway,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Angela, Froio, Danielle, Nagrial, Adnan M, Parkin, Ashleigh, Murphy, Kendelle J, Chin, Venessa T, Wohl, Dalia, Steinmann, Angela, Stark, Rhys, Drury, Alison, Walters, Stacey N, Vennin, Claire, Burgess, Andrew, Pinese, Mark, Chantrill, Lorraine A, Cowley, Mark J, Molloy, Timothy J, Waddell, Nicola, Johns, Amber, Grimmond, Sean M, Chang, David K, Biankin, Andrew V, Sansom, Owen J, Morton, Jennifer P, Grey, Shane T, Cox, Thomas R, Turchini, John, Samra, Jaswinder, Clarke, Stephen J, Timpson, Paul, Gill, Anthony J, Pajic, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Pancreas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241608/
https://www.ncbi.nlm.nih.gov/pubmed/29080858
http://dx.doi.org/10.1136/gutjnl-2017-315144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241608/
https://www.ncbi.nlm.nih.gov/pubmed/29080858
http://dx.doi.org/10.1136/gutjnl-2017-315144

Ejemplares similares